Article
Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.
Cancer discovery - 1 Oct 2016
Gainor Justin F, Dardaei Leila, Yoda Satoshi, Friboulet Luc, Leshchiner Ignaty, Katayama Ryohei, Dagogo-Jack Ibiayi, Gadgeel Shirish, Schultz Katherine, Singh Manrose, Chin Emily, Parks Melissa, Lee Dana, DiCecca Richard H, Lockerman Elizabeth, Huynh Tiffany, Logan Jennifer, Ritterhouse Lauren L, Le Long P, Muniappan Ashok, Digumarthy Subba, Channick Colleen, Keyes Colleen, Getz Gad, Dias-Santagata Dora, Heist Rebecca S, Lennerz Jochen, Sequist Lecia V, Benes Cyril H, Iafrate A John, Mino-Kenudson Mari, Engelman Jeffrey A, Shaw Alice T
Abstract excerpt
Advanced, anaplastic lymphoma kinase (ALK)-positive lung cancer is currently treated with the first-generation ALK inhibitor crizotinib followed by more potent, second-generation ALK inhibitors (e.g., ceritinib and alectinib) upon progression. Second-generation inhibitors are generally effective even in the absence of crizotinib-resistant ALK mutations, likely reflecting incomplete inhibition of ALK by crizotinib...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.